Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, announce an amendment to the existing terms of their previously announced merger agreement. Under the terms of the amended agreement, ACELYRIN stockholders will now receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, representing a meaningful increase in the ownership percentage of the combined company.
Read the full article: Alumis and ACELYRIN Announce Amended Merger Agreement //
Source: https://www.globenewswire.com/news-release/2025/04/21/3064525/0/en/Alumis-and-ACELYRIN-Announce-Amended-Merger-Agreement.html